Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
| 1.5 | |
| 1.53 | |
| - | |
| 1.567 | |
| 1.48 | |
| 1.48-8.17 | |
| 40 215 K | |
| 26 810 K | |
| 4 149 K | |
| -0.59 | |
| 1.579 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
A company’s size does not necessarily dictate the size of it’s returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that w...
Syros Pharmaceuticals, Inc. SYRS shares have skyrocketed 200% in the past three months compared with the industry’s rise of 13.1%. This clinical-stage company is developing its pipeline candidate, ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
